Q3 2025 Egetis Therapeutics AB (publ) Earnings Call Transcript
Key Points
- Egetis Therapeutics AB (STU:P0F) received Breakthrough Therapy Designation from the FDA for tiratricol, highlighting the urgent need for effective treatment for MCT8 deficiency.
- The company successfully completed the ReTRIACt study of Emcitate, showing positive results and enabling a rolling NDA submission in December 2025.
- Egetis has initiated commercialization of Emcitate in Europe and started market preparations in the US, with distribution deals in Turkey and the Gulf region.
- Revenue for the first nine months increased to SEK44.6 million from SEK35.3 million in the same period last year, indicating strong financial performance.
- The company strengthened its cash position with a net cash injection of SEK172 million from a directed rights issue, enhancing financial stability.
- The gross profit margin is lower than historical figures due to regulatory success and starting of depreciation, impacting financial results.
- The French Health Authority rejected the first reimbursement submission for Emcitate, requiring a resubmission with additional data, delaying market access in France.
- The ReTRIACt study required changes to the statistical analysis plan, indicating challenges in meeting initial study endpoints.
- The commercialization strategy in the US will require significant investment, with an expected increase in spending for building the commercial and medical affairs infrastructure.
- The process for reimbursement approval in France is expected to take one to two years, potentially delaying revenue generation in this market.
Welcome to Egetis Therapeutics Q3 report 2025. (Operator Instructions) Now I will hand the conference over to CEO, Nicklas Westerholm. Please go ahead.
()-
Thank you, operator, and good morning, everyone, and a warm welcome to Egetis Therapeutics quarter three results call planned for the coming 30 minutes. For those who I haven't had the privilege to meet before, I'm Nicklas Westerholm. I'm the CEO of the company. With me today, I also have Yilmaz Mahshid, Chief Financial Officer; Henrik Krook, Vice President, Commercial Operations; Karl Hard, Vice President, Investor Relations; and Christian Sonesson, Vice President, Product Strategy and Development.
So let's turn our attention to the topics to be covered today. I am very pleased with the great progress made during the quarter and post the period. Amongst others, FDA awarded us a Breakthrough Therapy Designation for tiratricol on the 14th of July this year. We had a very successful pre-NDA meeting
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
